June 8th, 2020 | 11:30 CEST
Aurora, Bayer, XPhyto - scalable growth markets with potential
Health is the most precious good in the life of a human being. The preservation and improvement of the quality of life is a large business area. Investors around the globe have the opportunity to participate in many different areas of research and development of products and therapies. The development of new markets and preparations usually requires a lot of risk capital before the fruits can be harvested. At the latest when a scalable solution has been found to improve people's lives, then the value of the company increases.
time to read: 1 minutes
|
Author:
Mario Hose
ISIN:
CA98421R1055 , CA05156X8843 , DE000BAY0017
Table of contents:
Author
Mario Hose
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Tag cloud
Shares cloud
Patches to treat diseases
The Canadian company XPhyto Therapeutics Corp. announced this morning that its wholly owned German subsidiary, Vektor Pharma TF GmbH, has completed the formula for its novel transdermal delivery system for the neurological drug Rotigotine. Vektor is now proceeding with the process implementation for the production of Rotigotine patches for human clinical trials.
The active ingredient Rotigotine is a generic and off-patent drug and is used for the treatment of Parkinson's disease and restless legs syndrome in Europe and the United States. The global market for Rotigotine patches was worth approximately CAD 250 million to CAD 500 million in 2019.
Results expected in 2020
"We are extremely pleased with the TDS development results thus far. It appears that our goal of optimizing the dosage form efficiency, to reduce the amount of drug required in each patch, and improving overall patch adhesion to the patient's skin has been achieved," said Prof. Dr. Thomas Beckert, founder and managing director of Vektor.
Once process implementation is complete, clinical sample manufacturing and analytical work will commence in Vektor's EU GMP laboratory and manufacturing facility based in Baden-Württemberg, Germany. Human pilot studies in Europe are scheduled for Q3 2020 with results expected in Q4 2020, according to today's announcement.
Newcomers with potential
The market value of XPhyto at the current share price level of EUR 2.11 is approximately EUR 116 million. Compared to other companies dealing with the topic of health the value is still low and at the same time expresses the potential. Aurora Cannabis has a market value of EUR 1.39 billion at a share price of EUR 12.57. With a market capitalisation of EUR 64.99 billion and a share price of EUR 66.62, the pharmaceutical giant Bayer is a heavyweight.
Usually every company starts small and XPhyto is positioned in promising and scalable growth markets with its German subsidiaries Bunker Pflanzenextrakte GmbH and Vektor Pharma TF GmbH.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.